no weight loss with tirzepatide obesity trial non-diabetic pros and cons for A 72-week compared the two leading GLP-1 medications in adults (no diabetes). The Tirzepatide outcompetes long-acting insulin in – TrimRX | Why Am I

GLP1, is an FDA approved medication that has been used to treat type II diabetes since 2017

The consistency and magnitude of tirzepatide's effect across diverse patient populations has made it the preferred choice for accelerated weight loss outcomes

Insurance coverage is actually higher than most people realize

Unexpected manufacturing problems, demand spikes, and tightened ingredient supply lines have all contributed to the shortages, which have subsequently caused treatment delays, medication switches and other hassles for doctors and patients

The peptide appears to engage several key pathways simultaneously